Severe insulin resistance as a complication of diabetes in pregnancy is seen with increasing frequency. Treatment with large doses of insulin (>300 units perday) can be practically difficult. A woman with preexisting Type 2 diabetes mellitus and poor glycemic control presented in early pregnancy requiring over 1000 units of insulin daily. She was transitioned to subcutaneous U-500 (concentrated regular insulin) in combination with a rapid-acting insulin analog achieving good glycemic control and good maternal and fetal outcomes. U-500R insulin in conjunction with a rapidacting insulin analog can be used safely in early pregnancy to improve glycemic control in severe insulin resistance due to pregestational diabetes.
Introduction
Approximately 1% of pregnancies in the United States are complicated by pregestational diabetes. The majority of these cases involve Type 2 diabetes, the prevalence of which is rapidly growing. 1 The insulin resistance of pregnancy, coupled with insulin resistance due to preexisting diabetes, can necessitate the use of large doses of insulin for adequate glycemic control. In extreme cases (defined as >200 units insulin per day), the volume of insulin needed to maintain adequate glucose control becomes logistically problematic and may ultimately decrease patient adherence. 2, 3 One solution is U-500R insulin, which is five times as concentrated (500 units ml À1 ) as U-100R insulin. There is an inverse relationship between the concentration of insulin injected and the rate of insulin absorbed, and thus U-500R and U-100R have different pharmacokinetic and pharmacodynamic profiles. Recent data in obese, nondiabetic individuals, suggest high-dose U-500 insulin has similar bioavailability to U-100R. However, there is a blunting of peak insulin concentrations and a longer time to peak concentration, maximum effect and duration of action with U-500R. 4, 5 With 100 unit doses of U-500R, time-to-peak concentration was estimated at 8 h, and duration of action at nearly 20 h. 4 We report the successful use of U-500R combined with aspart insulin during pregnancy in a woman with pregestational diabetes.
Case
A 27-year-old morbidly obese (BMI 43) gravida 4 para 0 with a 4 year history of poorly controlled Type 2 diabetes was admitted at 15 1/7 weeks gestation for a planned transition to subcutaneous U-500R insulin. The patient had a prior history of three spontaneous first-trimester abortions attributed to poor glycemic control and was variably adherent to her antidiabetic medications of neutral protamine hagedorn (NPH) insulin (40 units in the morning and 50 units at bedtime), metformin 1000 mg three times daily and glyburide 5 mg daily. During a preconception counseling visit, the patient was incidentally found to be pregnant. Glyburide was discontinued, NPH was increased and premeal aspart was added (taken immediately before eating). After 4 days her blood glucose remained extremely high (blood glucose 491 mg dl À1 ; HbA1C 11.3%) and she was admitted at 4 1/7 weeks gestation for glycemic control and education. Prenatal laboratory values were within normal limits and evaluation for Cushing's syndrome, lipodystrophy or other forms of syndromic insulin resistance were negative. She was discharged after 3 weeks on a total daily dose (TDD) of 690 units (basal NPH 220 units in the morning and 110 units at bedtime, premeal aspart 85, 100 and 115 units, presnack apart 20 units, and correctional aspart at 5 units per 50 mg dl À1 over 200 mg dl
À1
). Before discharge, a transvaginal ultrasound verified an intrauterine pregnancy with positive fetal cardiac motion.
After discharge the patient received daily follow up and her insulin dose was escalated to a TDD of 1100 units, necessitating 13 or more daily injections largely owing to the limits of a 100 unit insulin syringe. Despite the fact that her second-trimester HbA1C improved to 6.5%, her fasting capillary glucose values ranged from 70 to 100 mg dl À1 and postprandial values ranged from 140 to 280 mg dl
. She was thus readmitted at 15 1/7 weeks gestation for initiation of U-500R insulin (Eli Lilly, Indianapolis, IN, USA). On hospital day 3 the patient was given U-500R at 90% of her TDD divided into three premeal doses (Table 1) , a strategy loosely based on an algorithm for syndromic insulin resistance. 2, 6 As is typically done to prevent accidental overdose, U-500R was dosed in milliliters not units, and thus she was started on 0.66 ml (330 units) of U-500R premeals. Metformin was continued. Subsequent to and after her transition to U-500 insulin, the patient had several episodes of hypoglycemia throughout the day. Her insulin doses were therefore lowered, and she was given a bedtime snack. Owing to a severe 0200 hours low on hospital day 6, the predinner dose was lowered and split between dinner and a bedtime snack to prevent a late-night peak from a large dinnertime dose (Table 1) . Further insulin reductions were made over the next three days. She was ultimately discharged on hospital day 10 on a TDD of 600 units.
Anatomical fetal survey and fetal echo were normal at 19 weeks gestation. At 24 weeks gestation, the patient's glucose values ranged from 51 to 192 mg dl À1 while fasting and 75 to 263 mg dl À1 in the postprandial period. Owing to persistent fasting hypoglycemia, her bedtime U-500R was discontinued, and aspart was added with breakfast and dinner to address postprandial hyperglycemia. There was no significant change in TDD ( Table 2) . By 35 weeks gestation, in the setting of premeal hypoglycemia (50 to 70 mg dl À1 ) and persistent postprandial hyperglycemia (as high as 222 mg dl À1 ), there was further increase in premeal aspart and a decrease in U-500R insulin. TDD was reduced to 500 units. HbA1C at 35 weeks was 5.8%. At 36 6/7 weeks gestation, the patient Abbreviations: HD, Hospital Day; U-500, regular insulin with 500 units ml À1 ; U-100, combined dosing of NPH and aspart insulin with a concentration of 100 units ml À1 ; NA, not available; post, 1 h postmeal. Abbreviation: U-500, regular insulin with 500 units ml À1 .
U-500 insulin use in pregnancy I Okeigwe et al was found to have a low amniotic fluid index (5.4) and less than expected fetal interval growth. She underwent induction of labor, which progressed normally and vaginally delivered a 2955 g female infant with Apgars 6 and 8 at one and five minutes. The neonate was without complications and was discharged home along with her mother on postpartum day 2.
In anticipation of significantly reduced insulin requirements postpartum, the mother was transitioned back to NPH and aspart insulin. At 10 weeks postpartum, her TDD was 100 units with blood glucose values of 70 to 200 mg dl À1 .
Discussion
We report here a case of severe insulin resistance in pregnancy treated with subcutaneous U-500R insulin and a rapid-acting insulin analog. Although there have been case reports on the use of U-500 insulin in pregnancy via insulin pump, 7 subcutaneously in lipodystrophy with severe insulin resistance requiring up to 600 units h À1 , 8 and in a patient with pregestational diabetes where subcutaneous U-500 was initiated late in pregnancy (30 weeks), 9 this is the first report of the use of U-500R insulin in combination with a rapid-acting analog in pregnant or nonpregnant patients.
One unusual aspect of our case is that the patient's insulin requirements went down 50% after transition to U-500R insulin and continued to steadily decline through the third trimester. We strongly suspected poor adherence to her 13 þ shots a day outpatient regimen, suggesting she was not actually receiving a TDD of 1100 units before her second admission. Supporting this hypothesis, she developed hypoglycemia in the hospital on her theoretical outpatient dose and her final TDD of U-500R was very similar to her TDD after her first-trimester admission. In addition, the significantly improved glycemic control no doubt improved what was clearly very severe, early insulin resistance of pregnancy and this improvement perhaps lead to reduced insulin requirements later in pregnancy. However, we cannot be certain that there are not fundamental pharmacodynamic differences in pregnancy that resulted in this significant reduction in insulin need. Therefore, until further data is available in pregnant women on the appropriate transition dosing, it seems prudent to consider admission for a transition to U-500R insulin to avoid serious hypoglycemia. This also allows time for education of the patient and all members of the health care team about the risks of inadvertent overdosing and on dosing of U-500R in milliliters rather than units.
We chose to initiate insulin therapy when the patient was on a TDD of 1100 units a day and perhaps the transition should have been made earlier. Recommendations suggest, somewhat arbitrarily, using U-500R insulin in patients requiring 200 units or more of insulin a day. 2, 3 Given the potential safety issues, a higher threshold maybe appropriate in pregnancy. Patients requiring >100 units in a given dose (and thus more than one injection per dose) may have adherence issues as seen in our patient. Thus patients on >300 to 400 units per day maybe appropriate for consideration of U-500R.
Guidelines for frequency of dosing in nonpregnant patients 2, 3, 10 suggest that our patient should have received four times a day dosing. However, we were forced to discontinue the bedtime dose and significantly reduce the predinner dose to prevent fasting and nocturnal hypoglycemia. Therefore, for patients on 300 to 500 units of insulin a day, we recommend twice daily dosing initially (morning and dinner). For patients on 500 or more units a day, we recommend three times a day premeal dosing in uneven doses with the largest dose in the morning. However, for patients with lateevening hypoglycemia suggesting late peaking of dinner insulin, dosing U-500R morning and bedtime may be more appropriate.
As with any insulin use, the optimal regimen will have to be determined for each patient. Given the slower absorption and longer duration of U-500R, in pregnancy, where postprandial hyperglycemia is especially prominent, it is likely that augmentation with a rapid-acting analog will often be required for optimal control. Ultimately, our patient was receiving 27% of her daily insulin as a rapid-acting analog. If it is anticipated that this strategy will be used, one could consider a lower starting dose of U-500R insulin to allow for addition of the rapid-acting analog, targeting meals with the highest postprandial glucose levels first.
With a steady rise in the incidence of diabetes in pregnancy, the number of severely insulin resistant patients requiring innovative treatment strategies will only grow. Based on prescription data, use of U-500R insulin for diabetes has more than doubled since 2007, 4, 11 and its use during pregnancy is likely to also increase. We show that subcutaneous U-500R insulin can be used effectively in pregnancy to improve glycemic control in severe insulin resistance due to pregestational diabetes. Co-administration of insulin aspart works synergistically to target postprandial hyperglycemia. More experience in pregnancy is needed to better establish safety and definitive guidelines for use. Unfortunately, given the current diabetes epidemic, that experience is sure to come.
Conflict of interest
The authors declare no conflict of interest.
